Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and ...
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
The T1D Fund, an impact investment fund that focuses on solutions to treat, prevent and cure type 1 diabetes, on Wednesday ...
The stock market’s bullish sentiment for the magnificent seven stocks may weaken anytime. When that happens is not ...
The ETF comes with an expense ratio of 0.55% and mirrors the Alger Russell Innovation Index, which focuses on innovative ...
Headlines,GAMMA Investing LLC adjusts its holdings in STERIS,Institutional investors show increased interest in STERIS,Strong ...
24/7 Wall St. on MSN12h
Merck Just Paid Investors: How Much Did They Receive?Merck just rewarded its shareholders again with a dividend hike. This Dow stock has come with a quarterly dividend for almost ...
UBS lowered the firm’s price target on Pfizer (PFE) to $29 from $31 and keeps a Neutral rating on the shares as part of a broader note on the ...
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...
The stock's fall snapped a two-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback